Botulinum toxin in management of back pain
DOI:
https://doi.org/10.12775/QS.2024.15.51889Keywords
Botulinum toxin, botox, Low Back pain, myofascial pain syndrome, management, treatmentAbstract
Introduction
The botulinum toxin is a widely used therapeutic agent. It is used for aesthetic reasons in treatment of glabellar wrinkles. Therapeutic indications include cervical dystonia, hyperhidrosis or migrenes. Also, it can be used in pain management, especially back pain. Back pain is one of the most common pain syndromes decreasing quality of life. Treatment involves various methods such as conservative and surgical approach. One of the methods is botulinum toxin.
Objectives
This article aims to evaluate usage, mechanism and treatment effects of back pain using botulinum toxin.
Methods
A Literature review of articles published in Pubmed between 2000 and 2024 using following words “botulinum toxin”, “botulinum”, “back pain” and “treatment”.
Results
Botulinum toxin injections are one of the pain management methods used especially in low back pain and myofascial pain syndrome. Treatment relies on its myorelaxant properties and inhibition of neuromodulator secretion such as substance P or acetylocholine. Pain relief effects are noted after three weeks and can last up to six months. In the initial stages a significant amount of patients report relief of pain.
Conclusion
Botulinum toxin is one of the treatment methods for lower back pain. It is a safe, minimally invasive and effective treatment. Patients can feel the relief even in three weeks and the effects might persist even up to six months.
References
Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins (Basel). 2021 Jan 14;13(1):58. doi: 10.3390/toxins13010058. PMID: 33466571; PMCID: PMC7828686.
Kumar R, Dhaliwal HP, Kukreja RV, Singh BR. The Botulinum Toxin as a Therapeutic Agent: Molecular Structure and Mechanism of Action in Motor and Sensory Systems. Semin Neurol. 2016 Feb;36(1):10-9. doi: 10.1055/s-0035-1571215. Epub 2016 Feb 11. PMID: 26866491.
Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559-65. doi: 10.1007/s00702-007-0728-2. Epub 2007 Apr 26. PMID: 17458494.
Milanov I. (2014) Zespół bólowy kręgosłupa. Back pain. Pediatr. Med. Rodz. 10(3):253–264.
Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, Williams G, Smith E, Vos T, Barendregt J, Murray C, Burstein R, Buchbinder R. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Jun;73(6):968-74. doi: 10.1136/annrheumdis-2013-204428. Epub 2014 Mar 24. PMID: 24665116.
Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299. doi:10.21037/atm.2020.02.175
Casiano VE, Sarwan G, Dydyk AM, Varacallo M. Back Pain. In: StatPearls. Treasure Island (FL): StatPearls Publishing; December 11, 2023.
Jabbari B. Evidence based medicine in the use of botulinum toxin for back pain. J Neural Transm (Vienna). 2008;115(4):637-640. doi:10.1007/s00702-007-0864-8
Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes -an evidence based review. Toxicon. 2018 Jun 1;147:120-128. doi: 10.1016/j.toxicon.2018.01.017. Epub 2018 Feb 1. PMID: 29409817.
Carr WW, Jain N, Sublett JW. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications. Adv Ther. 2021 Oct;38(10):5046-5064. doi: 10.1007/s12325-021-01882-9. Epub 2021 Sep 13. PMID: 34515975; PMCID: PMC8478757.
Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019 Aug 5;11(8):459. doi: 10.3390/toxins11080459. PMID: 31387301; PMCID: PMC6723487.
Bellows S, Jankovic J. Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019 Aug 26;11(9):491. doi: 10.3390/toxins11090491. PMID: 31454941; PMCID: PMC6784164.
Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016 Oct 26;10(10):CD004314. doi: 10.1002/14651858.CD004314.pub3. PMID: 27782297; PMCID: PMC6461154.
Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9. doi: 10.1159/000370245. Epub 2015 Jan 21. PMID: 25613637.
Rahman E, Alhitmi HK, Mosahebi A. Immunogenicity to Botulinum Toxin Type A: A Systematic Review With Meta-Analysis Across Therapeutic Indications. Aesthet Surg J. 2022 Jan 1;42(1):106-120. doi: 10.1093/asj/sjab058. PMID: 33528495.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. AbobotulinumtoxinA. 2024 Feb 15. PMID: 33017112.
Trivedi MK, Kroumpouzos G, Murase JE. A review of the safety of cosmetic procedures during pregnancy and lactation. Int J Womens Dermatol. 2017 Feb 27;3(1):6-10. doi: 10.1016/j.ijwd.2017.01.005. PMID: 28492048; PMCID: PMC5418954.
Hudson C, Wilson P, Lieberman D, Mittelman H, Parikh S. Analysis of Breast Milk Samples in Lactating Women After Undergoing Botulinum Toxin Injections for Facial Rejuvenation: A Pilot Study. Facial Plast Surg Aesthet Med. 2024 Feb 2. doi: 10.1089/fpsam.2023.0326. Epub ahead of print. PMID: 38306172.
Wright G, Lax A, Mehta SB. A review of the longevity of effect of botulinum toxin in wrinkle treatments. Br Dent J. 2018 Feb 23;224(4):255-260. doi: 10.1038/sj.bdj.2018.126. PMID: 29472686.
Klimaszewska K, Krajewska-Kułak E, Kondzior D, Kowalczuk K, Jankowiak B. Quality of life in patients with lumbar spine pain syndromes. Nursing Problems / Problemy Pielęgniarstwa. 2011;19(1):47-54.
da C Menezes Costa L, Maher CG, Hancock MJ, McAuley JH, Herbert RD, Costa LO. The prognosis of acute and persistent low-back pain: a meta-analysis. CMAJ. 2012;184(11):E613-E624. doi:10.1503/cmaj.111271
Kuryliszyn-Moskal A. Terapia zespołów bólowych kręgosłupa lędźwiowo-krzyżowego – strategie postępowania. Reumatologia. 2009;47(6):368-371.
Zylicz Z, Krajnik M (2003) How does pain arise? The mechanism of pain.Pain neurophysiology for beginners. Polish Palliative Medicine 2(1): 49-56.
Institute of Medicine (US) Committee on Pain, Disability, and Chronic Illness Behavior, Osterweis M, Kleinman A, Mechanic D, eds. Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives. Washington (DC): National Academies Press (US); 1987.
Machado D, Kumar A, Jabbari B. Abobotulinum Toxin A in the Treatment of Chronic Low Back Pain. Toxins (Basel). 2016 Dec 15;8(12):374. doi: 10.3390/toxins8120374. PMID: 27983689; PMCID: PMC5198568.
Urits I, Burshtein A, Sharma M, et al. Low Back Pain, a Comprehensive Review: Pathophysiology, Diagnosis, and Treatment. Curr Pain Headache Rep. 2019;23(3):23. Published 2019 Mar 11. doi:10.1007/s11916-019-0757-1
Romanelli MR, Thayer JA, Neumeister MW. Ischemic Pain. Clin Plast Surg. 2020;47(2):261-265. doi:10.1016/j.cps.2019.11.002
Li TT, Liu ZY, Xiong L, Zhang ZW. Clinical efficacy of botulinum toxin type A in the treatment of fasciitis pain: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(30):e34461. doi:10.1097/MD.0000000000034461
Chochowska, Małgorzata & Wytra̧zek, M. & Marcinkowski, J.T. & Huber, Juliusz. (2012). Myofascial pain syndrome - Etiology, pathogenesis, symptomatology. Fizjoterapia. 20. 89-96. 10.2478/v10109-012-0012-3.
Leonardi G, Alito A, Portaro S, et al. Intramuscular injections of botulinum toxin for the treatment of upper back myofascial pain syndrome: A systematic review of randomized controlled trials. Eur J Pain. 2024;28(3):369-381. doi:10.1002/ejp.2198
Godoy IR, Donahue DM, Torriani M. Botulinum Toxin Injections in Musculoskeletal Disorders. Semin Musculoskelet Radiol. 2016 Nov;20(5):441-452. doi: 10.1055/s-0036-1594284. Epub 2016 Dec 21. PMID: 28002866.
Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001 May 22;56(10):1290-3. doi: 10.1212/wnl.56.10.1290. PMID: 11376175.
Gallien P, Nicolas B, Petrilli S, Kerdoncuff V, Lassalles A, Le Tallec H, Durufle A. Role for botulinum toxin in back pain treatment in adults with cerebral palsy: report of a case. Joint Bone Spine. 2004 Jan;71(1):76-8. doi: 10.1016/S1297-319X(03)00124-6. PMID: 14769528.
Ney JP, Difazio M, Sichani A, Monacci W, Foster L, Jabbari B. Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients. Clin J Pain. 2006 May;22(4):363-9. doi: 10.1097/01.ajp.0000174267.06993.3f. PMID: 16691090.
Jabbari B, Ney J, Sichani A, Monacci W, Foster L, Difazio M. Treatment of refractory, chronic low back pain with botulinum neurotoxin A: an open-label, pilot study. Pain Med. 2006 May-Jun;7(3):260-4. doi: 10.1111/j.1526-4637.2006.00147.x. PMID: 16712627.
Jazayeri SM, Ashraf A, Fini HM, Karimian H, Nasab MV. Efficacy of botulinum toxin type a for treating chronic low back pain. Anesth Pain Med. 2011 Fall;1(2):77-80. doi: 10.5812/kowsar.22287523.1845. Epub 2011 Sep 26. PMID: 25729661; PMCID: PMC4335729.
Cogné M, Petit H, Creuzé A, Liguoro D, de Seze M. Are paraspinous intramuscular injections of botulinum toxin a (BoNT-A) efficient in the treatment of chronic low-back pain? A randomised, double-blinded crossover trial. BMC Musculoskelet Disord. 2017 Nov 15;18(1):454. doi: 10.1186/s12891-017-1816-6. PMID: 29141611; PMCID: PMC5688690.
Sahoo J, Jena D, Viswanath A, Barman A. Injection Botulinum Toxin A in Treatment of Resistant Chronic Low Back Pain: A Prospective Open-Label Study. Cureus. 2021 Sep 8;13(9):e17811. doi: 10.7759/cureus.17811. PMID: 34660021; PMCID: PMC8500249.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Blanka Łuczak, Bianka Nowińska, Katarzyna Słychan, Izabela Hądzlik, Jan Piotrowski, Julia Biały-Karbowniczek, Klaudia Bulska, Patrycja Brzozowska, Andrzej Piela, Konrad Sławek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 150
Number of citations: 0